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RESEARCH
Chikungunya has had a substantial impact on public health 
because of the magnitude of its epidemics and its highly 
debilitating symptoms. We estimated the seroprevalence, 
proportion of symptomatic cases, and proportion of chron-
ic form of disease after introduction of chikungunya virus 
(CHIKV) in 2 cities in Brazil. We conducted the population-
based study through household interviews and serologic 
surveys during October–December 2015. In Feira de San-
tana, we conducted a serologic survey of 385 persons; 
57.1% were CHIKV-positive. Among them, 32.7% reported 
symptoms, and 68.1% contracted chronic chikungunya 
disease. A similar survey in Riachão do Jacuípe included 
446 persons; 45.7% were CHIKV-positive, 41.2% reported 
symptoms, and 75.0% contracted the chronic form. Our 
data confirm intense CHIKV transmission during the con-
tinuing epidemic. Chronic pain developed in a high propor-
tion of patients. We recommend training health profession-
als in management of chronic pain, which will improve the 
quality of life of chikungunya-affected persons.
Chikungunya is an emerging mosquitoborne disease caused by an alphavirus (chikungunya virus; CHIKV) 
from the Togaviridae family (1). Reports of outbreaks of 
chikungunya were not frequent until the beginning of the 
21st century; however, some serologic studies provided 
evidence that CHIKV had circulated in a sylvatic cycle in 
nonhuman primates (2). In 2004, an outbreak of chikungunya 
emerged in some Indian Ocean islands (Comoros, Sey-
chelles, and Mauritius) (2) and later spread to Reunion Is-
land; the 266,000 recorded cases represented an attack rate 
of 35% (3). In the following years, the disease circulated in 
Italy, France, and India (3), and in 2013 it was introduced in 
the Americas, causing an epidemic of nearly 2.6 million au-
tochthonous cases in >40 countries from the southern Unit-
ed States to Argentina through December 2017 (4). Along 
with Zika and dengue viruses, chikungunya virus has be-
come a substantial global public health threat, not only be-
cause of the high magnitude of the epidemics but also be-
cause it can produce highly debilitating clinical symptoms, 
including intense joint pain that can last for years (2). 
Brazil confirmed autochthonous cases of chikungunya 
in 2014 simultaneously in 2 regions: Northern, in Oiapoque/
Amazonas, caused by Asian genotype virus; and Northeast, 
in 2 cities (Feira de Santana and Riachão do Jacuípe-Bahia), 
caused by the East/Central/South African (ECSA) genotype 
(5,6). In 2015, there were 20,661 notified cases of this dis-
ease; 271,824 cases were notified in 2016 and 171,930 cases 
in 2017 through epidemiologic week 35. The disease has af-
fected >50% (2,829/5,570) of Brazilian municipalities (7).
In the Americas, scientific investigation on CHIKV 
seroprevalence is scarce; to date, only 6 studies have been 
published. Three of the published studies involved blood 
donors; 1 in Puerto Rico, with seroprevalence of 23.5% 
(8); 1 in Guadeloupe, with 48.1% seroprevalence; and 1 
in Martinique, with 41.9% seroprevalence (9). Another 
study used a convenience sample of a single laboratory of 
Saint Martin, whose seroprevalence was 16.9% (10), and 
the fifth used a sample from a small rural area population 
in Brazil, where seroprevalence was 20% (11). The only 
study in South America involving random sampling of ur-
ban population was in Nicaragua, where the seroprevalence 
was 32.8% (12). Thus, we consider it important to produce 
information on seroprevalence of CHIKV in urban areas 
of Brazil.
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SYNOPSIS
We estimated the seroprevalence of CHIKV 1 year 
after the introduction of the virus in the population of 2 
urban areas in Brazil, Feira de Santana and Riachão do 
Jacuípe-Bahia, that are affected by the ECSA genotype. 
We further report the proportion of symptomatic cases of 
chikungunya and the proportion of patients that had the 
chronic form of disease.
Methods
Study Design and Participants
We conducted a cross-sectional population-based study 
through household interviews and serologic survey during 
November–December 2015, involving residents in delimited 
areas of 2 cities, Feira de Santana and Riachão do Jacuípe. 
These cities, which reported early epidemics of chikungu-
nya in Brazil caused by ECSA genotype (5,6), are situated 
in Bahia state in northeastern Brazil (Figure 1), which has a 
hot, semiarid climate. In 2014, Feira de Santana had 612,000 
inhabitants and a population density of 457.4 inhabitants/
km2; Riachão do Jacuípe had 35,322 inhabitants and a popu-
lation density of 28.5 inhabitants/km2 (13). These cities did 
not have Aedes albopictus mosquito infestations; the only 
vector present was Ae. aegypti. The mean of Premise Index 
(PI) of Ae. aegypti mosquitoes in 2014 was 1.1% in Feira 
de Santana and 2.0% in Riachão do Jacuípe, according to 
the records of the Vectors Control Program of the Health 
Department of Bahia State in Salvador, Bahia.
The study sampling frame was the general popula-
tion of the 2 cities living in the epicenter area of the early 
chikungunya epidemics. To identify these epicenters, we 
georeferenced the cases of chikungunya notified to the De-
partment of Health of the 2 municipalities, from epidemio-
logic week (EW) 32 of 2014 to EW 11 of 2015, using the 
geographic network of the cartographic base of each city. 
We then plotted the cases in the respective census tracts 
and estimated the kernel density (14) to delimit the census 
tracts that reported the highest number of cases (Figure 2).
Fieldworkers visited all households in the selected ar-
eas (areas with the highest density of cases, or hotspots). 
For the general population survey, we invited all house-
hold members who were >1 year of age to take part in the 
study and have a questionnaire answered if they had lived 
in the city for the last >6 months. We estimated the sample 
size for this survey as 296 persons in the delimited area of 
Feira de Santana and 295 in the delimited area in Riachão 
do Jacuípe, and estimated 30% seroprevalence, 95% con-
fidence, and 80% power. The Research Ethics Committee 
of the Institute of Collective Health/Federal University of 
Bahia approved this study (no. 986.229 of 03/03/2015).
Procedures
For the general population survey, we conducted interviews 
using a semistructured questionnaire installed on tablets to 
register demographics, socioeconomics, household charac-
teristics, and health status, especially self-reported chikun-
gunya infection. We trained undergraduate students of health 
to visit all households in the area, explain the project objec-
tives, and, when allowed, collect participants’ signatures in 
the Free and Informed Consent Form (FICF) and carry out 
the interviews. For participants <18 years of age, we used the 
Term of Assent and a responsible adult signed the document.
After interviewing all residents in each house, we ran-
domly selected 1 to participate in the serologic survey. This 
random sample was without replacement. Thereafter, a labo-
ratory technician used a specific FICF and collected 5 mL of 
blood per venipuncture, in accordance with current biosafety 
standards, from consenting participants. Local laboratory 
staff separated the serum by centrifugation and conditioned 
it at –20°C. We transported the aliquots to the virology labo-
ratory of the Federal University of Bahia/Institute of Health 
Sciences, where we processed these samples. We used ELI-
SA (Euroimmun, Lübeck, Schleswig-Holstein, Germany) to 
identify specific antibodies against CHIKV IgM and IgG, ac-
cording to the manufacturer’s instructions (15). We consid-
ered any person with CHIKV IgM or IgG (or both) detected 
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Figure 1. Notified cases of chikungunya georeferenced by household in Feira de Santana (A; n = 1,339), and Riachão do Jacuípe (B; 
n= 1,536), Bahia state, Brazil, during epidemiologic week 32 of 2014 through week 11 of 2015. Inset maps show locations of Feira de 
Santana and Riachão do Jacuípe in Bahia state and Bahia state in Brazil.
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in the serum as CHIKV infected. The Euroimmun chikun-
gunya IgM kit considers a ratio between the extinction value 
of the sample by the extinction value of the calibrator given 
within the kit. The lower detection limit of the CHIKV ELI-
SA is ratio 0.05 IgM and 0.06 IgG. Samples with ratio <0.8 
are considered negative, and those >1.1 are positive.
To calculate the proportion of symptomatic persons, we 
considered those who declared they have had chikungunya 
disease; those who reported fever and arthralgia as disease 
symptoms, at minimum, from August 2014 through the in-
terview date; and those who had IgM- or IgG-positive tests. 
If the symptoms of joint pain, especially in extremities, had 
persisted for >3 months after the onset of the disease, we con-
sidered them in the chronic phase (16). We considered asymp-
tomatic those who reported they had not had CHIKV infection 
but who had positive results for CHIKV IgM, IgG, or both.
Statistical Analysis
We analyzed the data using SPSS version 22 (https://www.
ibm.com/analytics/data-science/predictive-analytics/spss-
statistical-software). We reported the incidence of CHIKV 
infection (total and according to the variables of interest) as 
percentages with a 95% CI. We used the Pearson χ2 test to 
assess statistically significant differences (p<0.05) for cat-
egorical variables.
Results
We georeferenced, by household, 1,339 cases of chikun-
gunya in Feira de Santana and 1,536 in Riachão do Jacuípe 
(Figure 1) and identified the 5 census tracts with the high-
est density of cases of this disease during the epidemic in 
each city (Figure 2). The Municipal Department of Health 
of Feira de Santana registered 164 suspected cases of 
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 4, April 2018 619
Figure 2. Density of notified 
cases of chikungunya by census 
tract in A) Feira de Santana 
and B) Riachão do Jacuípe, 
Bahia state, Brazil, during 
epidemiologic week 32 of 2014 
through week 11 of 2015. Yellow 
shaded areas with red borders 
indicate the census tracts in 
which most cases  
were concentrated.
SYNOPSIS
chikungunya disease in the selected 5 census tracts in 
George Américo neighborhood, corresponding to incidence 
of 52.3 cases/1,000 inhabitants. In Riachão do Jacuípe, the 
Department of Health reported 697 suspected cases in Alto 
do Cemitério neighborhood, corresponding to incidence of 
202.5 cases/1,000 inhabitants (Figure 3).
In the selected 5 census tracts of George Américo, 
there were 1,157 buildings (including uninhabited house-
holds and commercial spaces) and 3,135 inhabitants in a 
surface area of 0.283 km2 (11,081.7 inhabitants/ km2). Dur-
ing the survey, we visited 591 households and interviewed 
1,858 persons. In the selected 5 census tracts of Alto do 
Cemitério, there were 1,122 buildings in total and 3,441 
inhabitants in a surface area of 0.606 km2 (1,454.9 inhabit-
ants/km2). In this area, we visited 659 households and inter-
viewed 1,879 persons (Figure 3).
In George Américo, we invited 591 persons to be part 
of the serologic survey; 385 (65%) consented. We iden-
tified 220 (57.1%) persons, 80 male (36.4%) and 140 fe-
male (63.6%), who had CHIKV antibodies: 163 IgG, 25 
IgM, and 32 both. In Alto do Cemitério, the consent rate 
was similar, 446/659 persons (67.7%). We identified 204 
(45.7%) persons, 59 (28.9%) male and 145 (71%) female, 
who had CHIKV antibodies: 138 IgG, 38 IgM, and 28 
both. We considered 9 participants in each city (18 total) as 
negative for CHIKV because their CHIKV ELISA ratio 
was 0.8–1.1 (Table; Figure 3). The difference in the sero-
prevalence rates of the 2 study areas was statistically sig-
nificant (p = 0.001). The differences in distribution of sero-
prevalence by age group and sex between the study areas 
were not statistically significant.
Of the 220 persons with positive serologic test results 
in George Américo, 72 (32.7%) reported having been af-
fected by chikungunya (Table). The rate of symptomatic 
CHIKV infections was significantly higher in women 
(54/140, 38.6%) than in men (18/80, 22.5%) (p = 0.015). 
For specific age groups, the difference was statistically 
significant (p<0.001); participants 40–59 years of age 
(32/69, 46.4%) and >60 years age (19/33, 57.6%) had the 
highest prevalence among those participants who reported 
symptoms. In Alto do Cemitério, the rate of symptomatic 
cases was 41.2% (84/204 participants) (Table). The prev-
alence of symptomatic cases in women (61/145, 42.1%) 
was also higher than in men (23/59, 39.0%), but the dif-
ference was not statistically significant (p = 0.755). For 
specific age groups, similar to George Américo, the dif-
ference was statistically significant (p<0.034); the 40–59-
year (28/63, 44.4%) and >60-year (35/69, 50.7%) age 
groups had the highest prevalence among those partici-
pants who reported symptoms.
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Figure 3. Flowchart of serologic survey of chikungunya in residents of George Américo, Feira de Santana, and Alto do Cemitério, 
Riachão de Jacuípe, in Bahia state, Brazil, 2015. Number ranges in paretheses indicate 95% CIs.
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Among the cases of symptomatic CHIKV infection, 
the proportion of participants with symptoms that lasted 
>3 months (chronic chikungunya) was 49/72 (68.1%) in 
George Américo and 63/84 (75.0%) in Alto do Cemitério 
(Table). Considering the total number of study participants 
with positive serologic test results for CHIKV, the propor-
tion of infected persons with long-term manifestations of 
the disease was 49/220 (22.2%) in George Américo and 
63/204 (30.9%) in Alto do Cemitério. These proportions 
were 49/385 (12.7%) in George Américo and 63/446 
(14.1%) in Alto do Cemitério when calculated for the 
whole study population in each area.
The rate of chronic forms of chikungunya disease 
among symptomatic participants with positive CHIKV se-
rologic test results was higher in women than in men in both 
George Américo (40/54, 74.1% in women; 9/18, 50.0% 
in men) and Alto do Cemitério (54/61, 88.5% in women; 
9/23, 39.1% in men). This difference was statistically dif-
ferent in Alto do Cemitério (p<0.001), whereas the p value 
was borderline in George Américo (p = 0.058). Regarding 
the age of the symptomatic persons with positive CHIKV 
serologic test results, we found no statistically significant 
difference in the rate of chronic form in both study areas.
Discussion
Our population-based seroprevalence study of CHIKV 
conducted in urban areas of 2 cities in Brazil where the 
ECSA (5,6) genotype recently emerged showed that >45% 
of the study population had CHIKV antibodies. The results 
of CHIKV serosurveys previously conducted in countries 
on different continents have varied from 10.2% to 75% 
seroprevalence (17,18), depending on the type of popula-
tion studied and the time and intensity of the virus circula-
tion. Our study revealed a higher incidence of this virus 
infection, more than double the values reported in studies 
previously published in the Americas (8–11), except for 
the serosurveys conducted in Guadeloupe and Martinique, 
which showed values similar to ours; however, only adults 
eligible for blood donation were included in the population 
of that study (9). Our study indicates that all age groups 
and genders were similarly exposed to CHIKV infection 
in both George Américo and Alto do Cemitério, as sup-
ported by the absence of significant difference in CHIKV 
seroprevalence across those groups.
We conducted our survey 1 year after the introduction 
of CHIKV in this area; the high incidence of infection sug-
gests that the transmission of CHIKV was fast and intense. 
In addition, CHIKV circulation seems to have remained 
active, because CHIKV IgM was detected in >6% of the 
participants. However, some studies have shown that, un-
like other arboviruses, CHIKV IgM may persist for pro-
longed periods: 12–13 months (19) or up to 3 years (20) 
postinfection. Moreover, CHIKV RNA was found in peri-
vascular synovial macrophages in 1 patient 18 months after 
infection, suggesting that the virus may persist in organs 
or sites of immune privilege (21). Thus, late detection of 
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Table. Seroprevalence of CHIKV among survey participants reporting symptomatic, asymptomatic, and chronic infection, Bahia state, 
Brazil, 2015–2016* 
Patient characteristics 
George Américo, Feira de Santana 
 
Alto do Cemitério, Riachão do Jacuípe 
No. participants No. positive Prevalence, % No. participants No. positive Prevalence, % 
Age group, y†        
 1–19 88 46 52.3  45 17 37.8 
 20–39 123 72 58.5  109 55 50.5 
 40–59 121 69 57.0  144 63 43.8 
 >60 53 33 62.3  148 69 46.6 
 Total 385 220 57.1  446 204 45.7 
Sex        
 M 129 80 62.0  127 59 46.5 
 F 256 140 54.7  319 145 45.5 
 Total 385 220 57.1  446 204 45.7 
Serologic results       
 IgG 385 163 42.3  446 138 30.9 
 IgM 385 25 6.5  446 38 8.5 
 IgM and IgG 385 32 8.3  446 28 6.3 
 Total 385 220 57.1  446 204 45.7 
Self-reported chikungunya infection       
 Yes‡  220 72 32.7  204 84 41.2 
 No§ 220 148 67.3  204 120 58.8 
 Total 220 220 100.0  204 204 100.0 
Self-reported chronic form¶        
 Yes 72 49 68.1  84 63 75.0 
 No 72 23 31.9  84 21 25.0 
 Total 72 72 100.0  84 84 100.0 
*Selected area of each city. The difference in the seroprevalence rate of the 2 areas was statistically significant (p = 0.001). CHIKV, chikungunya virus. 
†Children <1 y of age were not included in the study. 
‡Attack rate of symptomatic CHIKV infection. 
§Attack rate of asymptomatic CHIKV infection. 
¶Percentage among positive symptomatic cases of CHIKV infection. 
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CHIKV IgM may represent prolonged viral circulation or 
the persistence of these antibodies in persons infected sev-
eral months ago. 
We cannot extrapolate our results for the entire popu-
lation living in these 2 cities because the surveys took place 
in areas with the highest density of chikungunya cases dur-
ing the first months of the epidemic, possibly constituting 
the diffusion poles of CHIKV. However, over time, other 
areas were becoming secondary sources of transmission, 
which resulted in the second epidemic wave, as other re-
searchers have observed in Feira de Santana (22). It is pos-
sible that the mean seroprevalence of CHIKV in the pop-
ulations of Feira de Santana and Riachão do Jacuípe has 
reached levels closer to those we found in the areas where 
most chikungunya cases were reported at the beginning of 
the epidemic. This same pattern of spread was observed af-
ter the emergence of dengue in urban spaces (23), evidenc-
ing once more the high vectorial capacity of the Ae. aegypti 
mosquitoes responsible for these epidemics (5).
The difference observed in the levels of seroprevalence 
between the 2 study areas may be due to different levels 
of vector infestation, human population density, or both. 
Data from the Brazilian Institute of Geography and Sta-
tistics show that the population density in the hotspots of 
Feira de Santana was 7 times higher than in the study area 
of Riachão do Jacuípe (13). However, the Premise Index 
recorded for Ae. aegypti mosquitoes in 2015 was lower in 
Feira de Santana than in Riachão do Jacuípe. 
The wide range in CHIKV seroprevalence worldwide 
could be explained by many reasons, such as climatic fac-
tors, vector control measures applied before and during 
outbreaks that affect levels of Ae. aegypti infestation, the 
previous level of immunity of the population, and the strain 
and genotype of CHIKV. The CHIKV seroprevalence data 
in our study reflect levels that may be found in other big 
cities, because it was a population-based survey conducted 
in urban areas. The 3 surveys in the Caribbean (in Marti-
nique, Guadeloupe, and Puerto Rico) used a convenience 
sample or were conducted in a rural community; low popu-
lation density is not the most favorable environment for the 
proliferation of Ae. aegypti mosquitoes, which are adapted 
mostly to urban areas (24).
The proportion of symptomatic persons among those 
CHIKV positive in our study was similar to the proportion 
reported by Sissoko et al. (25) in Mayotte (37.2%). Our 
study revealed that the rate of symptomatic CHIKV infec-
tions was higher in the 40–59- and >60-year age groups, 
similar to the results of other studies. However, despite the 
higher rate of symptomatic CHIKV infections in women 
than in men, this difference was significant only in George 
Américo. It is possible this difference reflects the levels of 
prior prevalence of rheumatologic diseases in women in the 
2 study populations.
The prevalence of long-term manifestations of CHIKV 
varies widely, ranging from 3% among pediatric patients 
<15 years of age (26) to 83% in a cohort of rheumatology 
patients (27). A recently published metaanalysis estimated 
that ≈50% of chikungunya patients have long-lasting re-
lated symptoms (28). In our study, the proportion of par-
ticipants who had long-term manifestations of the disease 
among persons with positive serologic test results and 
who reported symptoms of chikungunya reached 68.1% 
in George Américo and 75.0% in Alto do Cemitério. Our 
results are similar to those obtained in a cohort of rheuma-
tology patients in Reunion Island (France) (27), in which, 1 
and 2 years after disease onset, ≈80% of patients had rheu-
matic manifestations associated with chikungunya. Our 
results also indicate that, 1 year after the beginning of the 
CHIKV outbreak, >12% of persons in our study popula-
tions in both cities suffered from joint pain that precluded 
the performance of many habitual activities, affected their 
quality of life, required medical care, and increased absen-
teeism at work. Some studies have shown that the chronic 
phase of chikungunya can last for >2 years (27–30). Thus, 
because of extremely debilitating symptoms during the 
acute phase of chikungunya disease, elevated attack rates, 
and the high proportion of patients who develop long-last-
ing symptoms, CHIKV outbreaks can have a substantial 
impact on the overall health of the population.
Our serologic survey has some limitations. First, we 
conducted it in the epicenters of the epidemic, so the re-
sults could be overestimated and cannot be extrapolated to 
the whole city. The fact that symptoms were self-reported 
is a potential source of bias, because participants may not 
accurately remember the symptoms of a disease that oc-
curred 1 year earlier. In addition, we did not collect indica-
tors of vector infestation in the 2 study areas. Despite these 
limitations, our investigation is a relevant study to under-
stand the transmission of CHIKV of the ECSA genotype 
after its introduction into an urban population, in which the 
seroprevalence corresponds to the rate of infection attack.
This study revealed a worrying scenario that emerged 
after the introduction of CHIKV in Feira de Santana and Ri-
achão do Jacuípe. The virus has spread almost completely 
through the cities (22,31,32), and at least one third of the 
infected persons had symptoms. In addition, there was a high 
frequency of the chronic form of chikungunya. These results 
reveal how much the emergence of CHIKV in these 2 cit-
ies has altered the health status of a relevant portion of the 
population, especially women. It is possible that this is the 
scenario in many urban centers in Brazil that have experi-
enced epidemics of CHIKV infection. Studies have shown 
that several factors are strongly associated with risk of 
chronic chikungunya, including female sex, age >45 years, 
acute disease severity, and presence of anterior articular 
disease (19,27,33,34). Despite the evidence, there is still no 
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physiopathogenic explanation. However, because rheumatic 
diseases are more prevalent in women (35), it is plausible 
that CHIKV is a potential trigger for the onset or cornifica-
tion of arthralgia in a group more susceptible to rheumatic 
diseases. Intense and disabling articular pain is a common 
symptom of CHIKV infection; this pain does not always 
respond to routine medical drugs and so requires specific 
and often long-term pharmacologic treatment. In chikun-
gunya epidemic situations, the problems for patients do not 
end after the acute phase and decline of the transmission; a 
large proportion of those affected require continuous treat-
ment and adequate pain management with drugs that can 
cause serious side effects, such as corticosteroids, opiates, 
and chemotherapeutics (36,37), to minimize suffering. These 
sequelae also influence individual and collective productive 
capacity and affect the public health sector and the economy. 
It is urgent to expand national and international research for 
developing technologies and strategies for increasing the ef-
fectiveness of vector control programs, for synthesizing an-
tiviral drugs to mitigate the symptoms and chronic evolution 
of the disease, and, especially, for producing vaccines that 
can be used in populations vulnerable to CHIKV.
Secretaria Vigilância em Saúde/Fundo Nacional de Saúde/MoH 
Brazil provided financial support.
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